It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Osm1 and Frd1 are soluble fumarate reductases from yeast that are critical for allowing survival under anaerobic conditions. Although they maintain redox balance during anaerobiosis, the underlying mechanism is not understood. Here, we report the crystal structure of a eukaryotic soluble fumarate reductase, which is unique among soluble fumarate reductases as it lacks a heme domain. Structural and enzymatic analyses indicate that Osm1 has a specific binding pocket for flavin molecules, including FAD, FMN, and riboflavin, catalyzing their oxidation while reducing fumarate to succinate. Moreover, ER-resident Osm1 can transfer electrons from the Ero1 FAD cofactor to fumarate either by free FAD or by a direct interaction, allowing de novo disulfide bond formation in the absence of oxygen. We conclude that soluble eukaryotic fumarate reductases can maintain an oxidizing environment under anaerobic conditions, either by oxidizing cellular flavin cofactors or by a direct interaction with flavoenzymes such as Ero1.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea; R&D Center, Polus Inc., Incheon, South Korea
2 College of Pharmacy, Chung-Ang University, Seoul, South Korea
3 New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea
4 Department of Biochemistry, Yeungnam University, Gyeongsan, South Korea
5 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
6 College of Pharmacy and Yonsei, Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea
7 Division of Life Sciences, College of Life Science and Bioengineering, Incheon National University, Incheon, Republic of Korea